Format

Send to

Choose Destination
J Urol. 2015 Jan;193(1):325-30. doi: 10.1016/j.juro.2014.06.026. Epub 2014 Jun 13.

FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases.

Author information

1
Department of Urology, St. James's University Hospital, Leeds, United Kingdom.
2
Department of Histopathology, St. James's University Hospital, Leeds, United Kingdom.
3
Leeds Institute of Cancer and Pathology, St. James's University Hospital, Leeds, United Kingdom.
4
Institute of Pathology, University of Bern, Bern, Switzerland.
5
Department of Urology, University of Bern, Bern, Switzerland.
6
Institute of Pathology, University of Bern, Bern, Switzerland; Department of Urology, University of Bern, Bern, Switzerland.
7
Leeds Institute of Cancer and Pathology, St. James's University Hospital, Leeds, United Kingdom. Electronic address: m.a.knowles@leeds.ac.uk.

Abstract

PURPOSE:

FGFR3 is considered a good therapeutic target for bladder cancer. However, to our knowledge it is unknown whether the FGFR3 status of primary tumors is a surrogate for related metastases, which must be targeted by FGFR targeted systemic therapies. We assessed FGFR3 protein expression in primary bladder tumors and matched nodal metastases.

MATERIALS AND METHODS:

We examined matched primary tumor and nodal metastases from 150 patients with bladder cancer clinically staged as N0M0. Four samples per patient were incorporated into a tissue microarray and FGFR3 expression was assessed by immunohistochemistry. FGFR3 expression was tested for an association with categorical clinical data using the Fisher exact test, and with overall and recurrence-free survival by Kaplan-Meier analysis.

RESULTS:

Duplicate spots from primary tumors and lymph node metastases were highly concordant (OR 8.6 and 16.7, respectively, each p <0.001). Overall FGFR protein expression levels did not differ between primary and metastatic lesions (p = 0.78). Up-regulated expression was recorded in 53 of 106 evaluable primary tumor spots and 56 matched metastases. Concordance of FGFR3 expression levels in 79 matched primary tumor and metastasis specimens was high (OR 8.45, p <0.001). In 15 and 12 patients expression was up-regulated in only metastasis and in only the primary tumor, respectively. Overall and recurrence-free survival was not related to FGFR3 expression.

CONCLUSIONS:

FGFR3 expression in matched primary and metastasized bladder cancer specimens showed good but not absolute concordance. Thus, in most patients primary tumor FGFR3 status can guide the selection of FGFR targeted therapy.

KEYWORDS:

carcinoma; fibroblast growth factor; neoplasm invasiveness; neoplasm metastasis; receptor; type 3; urinary bladder

PMID:
24933362
DOI:
10.1016/j.juro.2014.06.026
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for White Rose Research Online
Loading ...
Support Center